Reactome | alectinib resistant ALK mutants don't bind alectinib

Schema > FailedReaction > Entries

alectinib resistant ALK mutants don't bind alectinib Show undefined attributes

authored	[InstanceEdit:9724129] Rothfels, Karen, 2021-03-22
category	transition
compartment	[Compartment:70101] cytosol [Compartment:876] plasma membrane
created	[InstanceEdit:9700663] Rothfels, Karen, 2020-09-16
crossReference	[DatabaseIdentifier:12020745] Mondo:0004992
dbId	9700656
disease	[Disease:1500689] cancer
displayName	alectinib resistant ALK mutants don't bind alectinib
edited	[InstanceEdit:9725664] Rothfels, Karen, 2021-03-30
entityFunctionalStatus	[EntityFunctionalStatus:9714044] loss_of_function of alectinib resistant ALK mutants [plasma membrane]
eventOf	[Pathway:R-HSA-9717316] alectinib-resistant ALK mutants - Homo sapiens
input	[ChemicalDrug:R-ALL-9699608] alectinib [cytosol] [DefinedSet:R-HSA-9700560] alectinib resistant ALK mutants [plasma membrane]
isChimeric	false
isInDisease	true
isInferred	false
literatureReference	[LiteratureReference:9713982] Rapid Acquisition of Alectinib Resistance in ALK-Positive Lung Cancer With High Tumor Mutation Burden [LiteratureReference:9713876] Anaplastic Lymphoma Kinase (ALK) Kinase Domain Mutation Following ALK Inhibitor(s) Failure in Advanced ALK Positive Non-Small-Cell Lung Cancer: Analysis and Literature Review [LiteratureReference:9713917] Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer [LiteratureReference:9713997] Secondary mutations at I1171 in the ALK gene confer resistance to both Crizotinib and Alectinib [LiteratureReference:9711845] Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib [LiteratureReference:9700317] ALK F1174V mutation confers sensitivity while ALK I1171 mutation confers resistance to alectinib. The importance of serial biopsy post progression [LiteratureReference:9700357] Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma [LiteratureReference:9717278] Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma [LiteratureReference:9715259] Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib
maxDepth	1
modified	[InstanceEdit:9830342] Matthews, Lisa, 2023-03-08
name	alectinib resistant ALK mutants don't bind alectinib
normalReaction	[Reaction:R-HSA-9700662] Liganded-ALK dimer binds type I ALK-binding TKIs
releaseDate	2021-06-09
reviewStatus	[ReviewStatus:9821382] five stars
reviewed	[InstanceEdit:9729891] Inghirami, Giorgio, 2021-05-04
schemaClass	FailedReaction
species	[Species:48887] Homo sapiens
stId	R-HSA-9700656
summation	[Summation:9714028] The following ALK mutants show resistance to alectinib: ALK...

Referrals

(hasEvent)

[Pathway:R-HSA-9717316] alectinib-resistant ALK mutants